Integra LifeSciences (IART) Misses Q3 EPS by 2c; offers guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.76, $0.02 worse than the analyst estimate of $0.78. Revenue for the quarter came in at $382.4 million versus the consensus estimate of $387.22 million.

GUIDANCE:

Integra LifeSciences sees FY2023 EPS of $3.10-$3.14, versus the consensus of $3.14. Integra LifeSciences sees FY2023 revenue of $1.541-1.547 million, versus the consensus of $1.555 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target